![Eric Venker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Venker
Vorstandsvorsitzender bei
IMMUNOVANT, INC.
Vermögen: 57 Mio $ am 31.05.2026
Profil
Derzeit ist Eric Venker Co-President & Chief Operating Officer bei Roivant Sciences Ltd, President & Chief Operating Officer bei Roivant Sciences, Inc. und Co-President & Chief Operating Officer bei Roivant Sciences GmbH (beides Tochtergesellschaften von Roivant Sciences Ltd.) sowie Co-President & Chief Operating Officer bei Montes Archimedes Acquisition Corp. Eric Venker ist außerdem Mitglied des Verwaltungsrats von Arbutus Biopharma Corp., Sio Gene Therapies, Inc., Aruvant Sciences, Inc. und Immunovant, Inc. Zuvor war er Vorsitzender des Housestaff Quality Council am Columbia University Medical Center. Eric Venker hat einen Doktortitel der Yale School of Medicine und einen Doktortitel des St. Louis College of Pharmacy.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,22 % | 22.05.2026 | 1.613.063 ( 0,22 % ) | 48 Mio $ | 31.05.2026 |
IMMUNOVANT INC 0,12 % | 07.04.2026 | 251.813 ( 0,12 % ) | 8 Mio $ | 31.05.2026 |
Aktive Positionen von Eric Venker
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOVANT, INC. | Vorstandsvorsitzender | 21.04.2025 |
| ROIVANT SCIENCES LTD. | Präsident | 01.01.2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Präsident | 01.01.2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Direktor/Vorstandsmitglied | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Präsident | 01.01.2018 |
Roivant Social Ventures, Inc.
 Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Direktor/Vorstandsmitglied | 01.01.2014 |
Ehemalige bekannte Positionen von Eric Venker
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 05.04.2023 |
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 25.05.2022 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Vorstandsvorsitzender | 01.01.2015 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Eric Venker
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
19
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
St. Louis College of Pharmacy
 St. Louis College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University Medical Center
 Columbia University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. |
